Cadherin-17 (CDH17): A Viable Target in Bispecific Antibodies or CAR-T Therapy to Fight Many Gastrointestinal Cancers!
Cadherin-17 (CDH17): A Viable Target in Bispecific Antibodies or CAR-T Therapy to Fight Many Gastrointestinal Cancers!Recent years have seen an increasing research towards immunotherapy for gastrointestinal cancers (GICs), such as monoclonal antibodies, bispecific antibodies, and CAR-T cell therapy. Some targets identification lies at t...
Detailed information

Exploring the Science of Influenza A Virus: What You Need to Know
Exploring the Science of Influenza A Virus: What You Need to KnowThe winter and spring seasons every year mark the peak period of influenza A virus outbreaks. Due to its numerous hosts in the natural environment and its high potential for mutation or recombination, each outbreak can c...
Detailed information

LY6G6D (LY6-G): A New Member of Lymphocyte Antigen-6 Family Holds Big Opportunities in Bispecific Antibody for CRC Treatment!
LY6G6D (LY6-G): A New Member of Lymphocyte Antigen-6 Family Holds Big Opportunities in Bispecific Antibody for CRC Treatment!Genentech, an innovative leader in large molecule pharmaceuticals, has developed a anti-LY6G6D/CD3 bispecific antibody (LY6G6D-TDB) for colorectal cancer (CRC) treatment in its earlier days. With an elaborately design, L...
Detailed information

CLDN3: Another Tight Junction Protein or New Drug Target, Interest in CLDN Family is Growing Fast!
CLDN3: Another Tight Junction Protein or New Drug Target, Interest in CLDN Family is Growing Fast!Now, as the Claudins continue to be explored, interest in emerging Claudins is growing fast! Claudins are the key constituent proteins of tight junction (TJ) proteins. TJ proteins play crucial roles of cell-cell adhesion...
Detailed information

PROM1 (CD133): A New Cell Surface Marker of Cancer Stem Cells (CSCs), A More Significant Target for Immunotherapy!
PROM1 (CD133): A New Cell Surface Marker of Cancer Stem Cells (CSCs), A More Significant Target for Immunotherapy!A study published in Science Translational Medicine recently made a big splash. The article entitled "Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative gli...
Detailed information

TPBG/5T4: the Oncofetal Protein, an Appealing Target for ADC or Vaccine Therapeutics in Tumors!
TPBG/5T4: the Oncofetal Protein, an Appealing Target for ADC or Vaccine Therapeutics in Tumors!TPBG/5T4 has been so appealing recently to pharmaceutical companies as it yields encouraging results in tumor therapies. ClinicalTrial noted that there are over 10 TPBG-targeted drugs in clinical development. Notably, Ox...
Detailed information

Categories over 10000! --Rare diseases that are no longer
Categories over 10000! --Rare diseases that are no longer "Porcelain doll", "sticky baby" ... behind these seemingly beautiful words is the abyss of pain. It is reported that more than 350 million people in the world are suffering from rare diseases. Statistics show that the pr...
Detailed information

Mucin-17/MUC17: An Unexpected Target for Tumor Immune Therapy, Notably Gastric Cancer!
Mucin-17/MUC17: An Unexpected Target for Tumor Immune Therapy, Notably Gastric Cancer!Lately, there is robust evidence that mucins play a crucial role in tumor formation, cell adhesion, immune response, and cell signaling. Typically, several mucins have become hot targets for tumor immunotherapy, such as ...
Detailed information

VSIG4: a Prominent B7 Family Costimulatory Molecule or Complement Receptor in Cancers and Inflammatory Diseases!
VSIG4: a Prominent B7 Family Costimulatory Molecule or Complement Receptor in Cancers and Inflammatory Diseases!On November 28, 2022, Cancer Letters reported a review paper entitled "The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer", which describes the prominent roles of VSI...
Detailed information

Epitope Tags Overview
Epitope Tags OverviewIn 1984, S Munro and H R Pelham developed a technique to promote the purification and detection of recombinant proteins, in which an oligonucleotide encoding a peptide was fused to the protein of interest and the target ...
Detailed information

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1